{"id":457496,"date":"2025-05-19T00:00:00","date_gmt":"2025-05-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0027-2025-biopharma-colorectal-cancer-unmet-need-unmet-need-previously-treated-braf-mutant-or-ras-mutant\/"},"modified":"2026-03-31T10:26:12","modified_gmt":"2026-03-31T10:26:12","slug":"unneon0027-2025-biopharma-colorectal-cancer-unmet-need-unmet-need-previously-treated-braf-mutant-or-ras-mutant","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0027-2025-biopharma-colorectal-cancer-unmet-need-unmet-need-previously-treated-braf-mutant-or-ras-mutant\/","title":{"rendered":"Colorectal Cancer &#8211; Unmet Need &#8211; Unmet Need &#8211; Previously treated BRAF-mutant or RAS-mutant metastatic colorectal cancer (US\/EU)"},"content":{"rendered":"<p>The treatment landscape for second- and later-line metastatic colorectal cancer with <i><abbr data-abbreviation-entity=\"8174\" title=\"B-Raf proto-oncogene, serine\/threonine kinase\">BRAF<\/abbr><\/i> or <i><abbr data-abbreviation-entity=\"6567\" title=\"rat sarcoma\">RAS<\/abbr><\/i> mutations is rapidly changing following the market entry of biomarker-specific combination therapies.<i> <\/i>The <abbr data-abbreviation-entity=\"8174\" title=\"B-Raf proto-oncogene, serine\/threonine kinase\">BRAF<\/abbr> inhibitor Braftovi, combined with Erbitux, is redefining the treatment of <i><abbr data-abbreviation-entity=\"8174\" title=\"B-Raf proto-oncogene, serine\/threonine kinase\">BRAF<\/abbr><\/i>-mutant disease, while Krazati, targeting the <i><abbr data-abbreviation-entity=\"5343\" title=\"Kirsten rat sarcoma viral oncogene homolog\">KRAS<\/abbr><\/i> G12C mutation and paired with Erbitux, represents a significant advance in the treatment of <i><abbr data-abbreviation-entity=\"6567\" title=\"rat sarcoma\">RAS<\/abbr><\/i>-mutant disease. Established therapies such as Erbitux, Vectibix, Zaltrap, Lonsurf, and bevacizumab remain key players, but intensifying competition continues to shape the market. Given the ongoing demand for more-effective, better-tolerated therapies, drug developers must stay ahead of prescribing trends, pricing shifts, and emerging competitors to successfully navigate this market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which key factors drive medical oncologists\u2019 prescribing decisions for previously treated <i><abbr data-abbreviation-entity=\"8174\" title=\"B-Raf proto-oncogene, serine\/threonine kinase\">BRAF<\/abbr><\/i>-mutant or <i><abbr data-abbreviation-entity=\"6567\" title=\"rat sarcoma\">RAS<\/abbr><\/i>-mutant metastatic colorectal cancer?<\/li>\n<li>How do targeted therapies such as Braftovi and Krazati compare with other brands on key clinical attributes?<\/li>\n<li>Where are the biggest gaps in drug treatment, and how can new therapies capitalize on these opportunities?<\/li>\n<li>What trade-offs are medical oncologists willing to make between clinical benefits, side effects, and cost when choosing second- and third-line treatments?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 30 European medical oncologists fielded in March 2025<\/p>\n<p><strong>Key drugs:<\/strong> Braftovi, Krazati, Erbitux, Vectibix, Zaltrap, Lonsurf, bevacizumab<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>KEY FEATURE<\/strong><\/p>\n<p>Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-457496","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/457496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/457496\/revisions"}],"predecessor-version":[{"id":457856,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/457496\/revisions\/457856"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=457496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}